Side-by-side comparison of AI visibility scores, market position, and capabilities
Durham NC YC W23 Medicare-covered at-home pulmonary rehab for 16M US COPD patients shipping Kivo Kit; $475K MassMutual/Samsung NEXT-backed competing with Propeller Health for virtual respiratory rehabilitation at the 3-5% treatment gap.
Kivo Health is a Durham, North Carolina-based telehealth company — backed by Y Combinator (W23) with $475,000 raised from MassMutual Ventures, Samsung NEXT Ventures, Heuristic Capital, Quint Ventures, and SNR Ventures — providing Medicare-covered 8-week pulmonary rehabilitation programs to patients with chronic obstructive pulmonary disease (COPD), asthma, bronchitis, and other chronic lung conditions through an at-home telehealth delivery model that ships comprehensive Kivo Kits (containing an iPad pre-loaded with the Kivo platform and monitoring equipment) directly to patients' homes for virtual respiratory therapist sessions, structured exercise programs, and lung function monitoring. Founded in 2021 by founders with medical backgrounds and targeting the 16 million US patients with chronic lung conditions who represent $50 billion in annual healthcare spending.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.